Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

I think the AstraZeneca share price could be in for another great decade

I think the AstraZeneca share price could be in for another great decade. Despite a few weak years when AstraZeneca (LSE:AZN) was struggling, its share price has soared by 160% over the past 10 years, easily beating the FTSE 100‘s 45% rise. That certainly wasn’t a surprise, and wouldn’t have had such a big impact if the company had been investing sufficiently in its drug development pipeline to produce a stream of new candidates. But it hadn’t been doing that, and had diversified into all sorts of retail medical-related products (where it didn’t really have any significant competitive advantage). The turnaround started with the appointment of Pascal Soriot as the firm’s new chief executive in 2012, with the share price starting its climb a year later. Soriot’s turnaround plan included the disposal of the firm’s non-core businesses, and a renewed focus on research and development.

First found on: uk.finance.yahoo.com And then on: 1 other references